Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

LONGEVERON INC.

(LGVN)
  Report
Delayed Nasdaq  -  04:00 2022-09-23 pm EDT
4.040 USD   +1.76%
09/15Longeveron Names Jerome Bailey Vice President of Business Operations
AQ
09/06Longeveron to Present at H.C. Wainwright 24th Annual Global Investment Conference
AQ
09/01LONGEVERON INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Longeveron to Announce Fourth Quarter and Full Year 2021 Financial Results, on March 11, 2022

03/07/2022 | 08:01am EDT

MIAMI, March 07, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the Company will release its fourth quarter and year-end 2021 financial results on Friday, March 11, 2022 before the open of U.S. financial markets. Management will host a conference call to discuss the Company’s financial results and provide a corporate update on the same day at 8:30 a.m. EST.

Dial-in Number
U.S. Dial-in Number: 844-200-6205
Canada Dial-in Number: 833-950-0062
All Other Locations Dial-in Number: 929-526-1599
Conference ID: 770734

U.S. Replay Dial-in Number: 929-458-6194
Canada Replay Dial-in Number: 226-828-7578
All Other Locations Dial-in Number: 44-204-525-0658
Conference ID: 443753

An audio webcast of the call may also be accessed from the ‘Investors’ page of the Longeveron website at www.longeveron.com. A replay of the call will be available on the Longeveron website shortly after completion of the call.

About Longeveron

Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization, and broad use by the healthcare community. Additional information about the Company is available at www.longeveron.com.

INVESTORS & MEDIA:

Investors:
Brendan Payne
Stern Investor Relations
Tel: (212) 362-1200
Email: Brendan.payne@sternir.com

Media:
Neil Hare
GVC Strategies
Tel: (202) 550-0297
Email: neil@gvcstrategies.com


Primary Logo

Source: Longeveron

2022 GlobeNewswire, Inc., source Press Releases

All news about LONGEVERON INC.
09/15Longeveron Names Jerome Bailey Vice President of Business Operations
AQ
09/06Longeveron to Present at H.C. Wainwright 24th Annual Global Investment Conference
AQ
09/01LONGEVERON INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
08/31Longeveron Says FDA Gives Lomecel-B Fast Track Designation to Treat Hypoplastic Left He..
MT
08/31U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for Longeveron's ..
AQ
08/31U.S. Food and Drug Administration Grants Fast Track Designation for Longeveron's Lomece..
CI
08/31Longeveron Gets FDA Fast-Track Designation for Lomecel-B in Heart Defect
DJ
08/25Longeveron Secures European Patent for Methods to Monitor Cell Therapy; Shares Rise Pre..
MT
08/25Longeveron Receives Intent to Grant Notice from the European Patent Office for Methods ..
AQ
08/25Longeveron Receives Intent to Grant Notice from the European Patent Office for Methods ..
CI
More news
Analyst Recommendations on LONGEVERON INC.
More recommendations
Financials (USD)
Sales 2022 0,97 M - -
Net income 2022 -16,8 M - -
Net Debt 2022 - - -
P/E ratio 2022 -4,81x
Yield 2022 -
Capitalization 84,8 M 84,8 M -
Capi. / Sales 2022 87,5x
Capi. / Sales 2023 125x
Nbr of Employees 19
Free-Float 23,5%
Chart LONGEVERON INC.
Duration : Period :
Longeveron Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LONGEVERON INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 4,04 $
Average target price 18,02 $
Spread / Average Target 346%
EPS Revisions
Managers and Directors
K. Chris Min Chief Executive & Medical Officer
James Clavijo Chief Financial Officer & Treasurer
Joshua M. Hare Chairman & Chief Scientific Officer
Jerome Bailey Vice President-Business Operations
Neil E. Hare Independent Director
Sector and Competitors
1st jan.Capi. (M$)
LONGEVERON INC.-66.53%85
MODERNA, INC.-51.32%48 368
IQVIA HOLDINGS INC.-32.86%35 330
LONZA GROUP AG-41.68%33 599
SEAGEN INC.-9.96%25 673
ALNYLAM PHARMACEUTICALS, INC.18.40%24 099